VC
TARS icon

VarCov Co’s Tarsus Pharmaceuticals TARS Stock Holding History

VarCov Co’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$822K Sell
13,057
-1,818
-12% -$116K 0.31% 109
2026
Q1 		$1.04M Buy
+14,875
New +$1.04M 0.39% 76

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VarCov Co's TARS Position: Q2 2026 in Review

VarCov Co reduced its Tarsus Pharmaceuticals (TARS) stake by 12% in Q2 2026, selling an estimated $116K and leaving 13,057 shares worth $822K. The position accounts for 0.31% of the portfolio, ranked #109.

VarCov Co first reported a position in TARS in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.04M in Q1 2026. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • VarCov Co held 13,057 shares of Tarsus Pharmaceuticals worth $822K as of Q2 2026.
  • VarCov Co sold 1,818 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $116K.
  • Tarsus Pharmaceuticals made up 0.31% of VarCov Co's portfolio in Q2 2026, its #109 holding.
  • VarCov Co first reported a position in Tarsus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • VarCov Co's Tarsus Pharmaceuticals position peaked at $1.04M in Q1 2026.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on VarCov Co's 13F filing for Q2 2026, filed 14 Aug 2026.